Cargando…

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO(2) ≤ 96% despite O(2)-support ≥ 6 L/min) without invasive mechanical ventilation wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Benjamin, Nguyen, Lee S., Zimmermann, Philippe, Boucenna, Faiza, Dubret, Louis, Baucher, Louise, Guillot, Helene, Bouldouyre, Marie-Anne, Allenbach, Yves, Salem, Joe-Elie, Barsoum, Paul, Oufella, Arezki, Gros, Helene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603074/ https://www.ncbi.nlm.nih.gov/pubmed/33080877 http://dx.doi.org/10.3390/ph13100317

Ejemplares similares

Intérêt d’une dose unique de Tocilizumab 400 mg sur les formes sévères d’infection respiratoire à COVID-19
por: Rossi, B., et al.
Publicado: (2020)

Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients
por: Allenbach, Yves, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
por: Roumier, Mathilde, et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Tocilizumab: Secondary organising pneumonia: case report
Publicado: (2022)

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
por: Hermine, Olivier, et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia
por: Agirbasli, Mehmet, et al.
Publicado: (2021)

341. Evaluation of Antimicrobial Use and Prescribing Patterns During the COVID-19 Pandemic in Patients Receiving Tocilizumab
por: Barsoum, Barbara, et al.
Publicado: (2021)

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
por: Capra, Ruggero, et al.
Publicado: (2020)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Organizing Pneumonia Induced by Tocilizumab in a Patient with Rheumatoid Arthritis
por: Gouveia, Pedro A, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
por: Górgolas Hernández-Mora, Miguel, et al.
Publicado: (2021)

Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab
por: Comel, Andrea Claudio, et al.
Publicado: (2020)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Tocilizumab: Lobar pneumonia following off label use: case report
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Methylprednisolone/tocilizumab: Fungal sepsis and pseudomonal pneumonia: 2 case reports
Publicado: (2021)

342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
por: Warner, Adam, et al.
Publicado: (2021)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis
por: Chen, Chi-Chung, et al.
Publicado: (2022)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study
por: Anci, Cynthia, et al.
Publicado: (2023)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
por: Macatangay, M.V.R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dtdtp958fa8qdrv6u31ujtt316